These findings further strengthen the mechanistic and translational rationale of Hybridopa™ and support its progression toward a Phase III clinical trial
July 1, 2026
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
These findings further strengthen the mechanistic and translational rationale of Hybridopa™ and support its progression toward a Phase III clinical trial